Related references
Note: Only part of the references are listed.Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia
Lei Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients
Jonathan K. Armstrong et al.
CANCER (2007)
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase
Shotaro Iwamoto et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia
Beata Zalewska-Szewczyk et al.
LEUKEMIA & LYMPHOMA (2007)
Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse:: A children's oncology group study (CCG-1941)
Mohammad Jarrar et al.
PEDIATRIC BLOOD & CANCER (2006)
Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia - Children's Cancer Group Study CCG-1961
EH Panosyan et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2004)
Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia
DS Hawkins et al.
CLINICAL CANCER RESEARCH (2004)
Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia
LJ Hak et al.
LEUKEMIA (2004)
Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL
JM Appel et al.
LEUKEMIA (2003)
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia:: a Children's Cancer Group study
VI Avramis et al.
BLOOD (2002)
Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac:: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system
BK Albertsen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries
BK Albertsen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment
HJ Müller et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia
B Wang et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2000)
Share Paper
